Odisha Approves Pharma & MedTech Policy to Build Sector Hubs & Boost Investment

The new policy will help Odisha build a competitive ecosystem for pharmaceutical and MedTech manufacturing, offering investors modern infrastructure, incentives and streamlined approvals to scale operations.

The Odisha Cabinet has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.

The policy is expected to drive large-scale investment and accelerate the development of sector-specific industrial clusters equipped with advanced infrastructure and streamlined regulatory processes.

Announcing the approval, Chief Secretary Pradeep Kumar Jena said the new policy will give Odisha a stronger presence in India’s expanding healthcare manufacturing landscape. “The Pharma and MedTech sector have significant potential for growth,” he noted.

Adding that the policy aims to support investors with incentives, land availability and plug-and-play facilities to help companies scale faster.

The initiative includes the creation of dedicated industrial hubs to attract pharmaceutical companies, bulk drug manufacturers, diagnostic device producers and MedTech innovators.

Industries Secretary Hemant Sharma highlighted that the policy is designed to help Odisha tap into rising demand for domestic manufacturing. “We see this as an opportunity to build a reliable, high-quality ecosystem that supports both innovation and large-scale production,” he said.

By expanding manufacturing capacities within the state, Odisha aims to strengthen supply chains and provide a conducive environment for research, technology upgrades and global export opportunities.

The Cabinet also emphasized the policy’s potential to create high-skilled employment and foster industry-academia collaboration across pharmaceuticals and MedTech.

Hemant Sharma mentioned the state is prepared to offer investor-friendly support. “Our focus is on creating long-term value for companies and ensuring Odisha becomes a preferred destination for the life sciences sector.”

With the policy now in place, the government is expected to initiate development work within planned industrial zones and begin outreach to domestic and international manufacturers.

Related Posts

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer in US

New Delhi: Sun Pharmaceutical Industries Limited has announced that UNLOXCYT (cosibelimab-ipdl) is now available in the United States for prescription by healthcare professionals for the treatment of adults with metastatic…

Unlicensed medical device stock worth Rs. 4.47 lakh seized in Gurugram raid

In a significant crackdown on the illegal sale of medical equipment, a team of drug control officers in Haryana conducted a high-profile raid at a private firm in Gurugram on…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer in US

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer in US

Unlicensed medical device stock worth Rs. 4.47 lakh seized in Gurugram raid

Unlicensed medical device stock worth Rs. 4.47 lakh seized in Gurugram raid

Controlled substances charge: Court summons Ramdev, Amazon founder

Controlled substances charge: Court summons Ramdev, Amazon founder

Allahabad HC refuses to quash case against pharma company linked to cough syrup deaths in Uzbekistan

Allahabad HC refuses to quash case against pharma company linked to cough syrup deaths in Uzbekistan

IPC registers 44 small-scale medtech firms under ADRMS

IPC registers 44 small-scale medtech firms under ADRMS

Over 9,000 deaths due to respiratory diseases in Delhi

Over 9,000 deaths due to respiratory diseases in Delhi